Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

Mineralys Therapeutics Inc

OPKO Health

PacWest Bancorp

Precigen

Paramount Group

Purple Innovation

B. Riley Financial

Summit Therapeutics

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Vera Therapeutics

Strong Small-Cap Insider Buys: Q1 2023

Arrival Group

Party City Holdco

Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company's stock (by “shorting” it) are forced to buy back their shares to cut their losses.

3 Short-Squeeze Stocks to Keep on Your Radar

Cassava Sciences (NASDAQ: SAVA ) stock rose 11% overnight after director Richard Barry said he bought shares worth $2.3 million. The company is working on an Alzheimer's drug called Simufilam.

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

Cassava Sciences (NASDAQ: SAVA) stock price has been in a steep sell-off in the past few months as the enthusiasm of its pipeline wanes. Shares of the biopharmaceutical company were trading at $24.9 on Wednesday, ~51% below the highest level in 2022.

Cassava Sciences stock price outlook is bearish despite insider buy

Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly.

Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things

AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the year ended December 31, 2022, and provided operating updates. Simufilam is Cassava Sciences' oral drug candidate for the proposed treatment of Alzheimer's disease dementia.

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

Eli Lilly

Newamsterdam Pharma Co NV

One in every nine seniors is living with Alzheimer's disease, and the race to cure it is worth big money. While the FDA has approved some Alzheimer's disease drugs, these can only slow the progression, not halt or reverse it.

3 Drug Stocks to Watch as Alzheimer's Clinical Trials End

AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer's disease dementia. Simufilam, an oral drug, is Cassava Sciences' proprietary lead drug candidate.

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease

It isn't about running out of money, but it's still laden with risk.

3 Big Reasons to Sell Cassava Sciences Stock Right Now

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a clinical-stage biotechnology firm that develops drugs for Alzheimer's disease (AD).

Cassava Sciences Stock Undervalued with Its $124 Price Target?

Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer's disease. The market reacted negatively anyway.

Cassava Sciences' Data Once Again Misunderstood

Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly.

Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile

One of the biggest decliners in today's market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today's trough on the company's announced mid-stage results for its Alzheimer's treatment.

Why Is Cassava Sciences (SAVA) Stock Down 20% Today?

Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors appeared first on Investor's Business Daily.

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

AUSTIN, Texas, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. This was an open-label safety study with exploratory efficacy endpoints. The study enrolled over 200 patients with mild-to-moderate Alzheimer's disease (MMSE 16-26). Study participants were administered open-label simufilam tablets 100mg twice daily for 1 year or more. Endpoints were measured at baseline (study entry) and month 12.

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer's Disease

Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also surging.

Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?

Anavex Life Sciences

Axonics ModulationTechnologies Inc

MannKind

Neurocrine Biosciences

Vertex Pharmaceuticals

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.

6 Favorite Biotech Bets For 2023

AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered.

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

Its oral drug candidate for Alzheimer's disease dementia has an upcoming readout. In other news, Cassava went on the legal counter-offensive against short sellers.

Cassava Sciences Drama Coming To A Head

The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well.

Why Is Cassava Sciences (SAVA) Stock Up 10% Today?

AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzheimer's disease. This study was designed to evaluate long-term drug safety and to measure cognitive changes (ADAS-cog) over 12 months in approximately 200 patients with mild-to-moderate Alzheimer's disease treated with open-label simufilam 100 mg twice daily. Simufilam is Cassava Sciences' oral drug candidate for Alzheimer's disease dementia.

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer's Disease

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million.

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

The shares of Cassava Sciences Inc  (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.

Cassava Sciences Stock's Bull Signal Has Never Been Wrong

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offering. The closing of the offering is expected to occur on or about November 22, 2022, subject to the satisfaction of customary closing conditions.

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

Bed Bath & Beyond

Credit Suisse

LM Ericsson Telefon

Hyzon Motors

TuSimple Holdings

High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.

7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022

News for Cassava Sciences Inc Stock (SAVA)